Drugs / Empaglifozin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04271189 | Sep 2020 → Aug 2024 | — | Azienda Ospedaliero-Universitaria di Parma | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05032001 | Aug 2021 → Aug 2022 | abdominal obesity-metabolic syndrome, type 2 diabetes mellitus | Metabolic Research Unit | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Empaglifozin | “Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day” NCT05032001 ↗ |